159 related articles for article (PubMed ID: 37491906)
1. Lowering Expectations: Glucocorticoid Tapering Among Veterans With Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy.
Wallace BI; England BR; Baker JF; Rojas J; Sauer BC; Roul P; Kunkel GA; Braaten TJ; Petro A; Mikuls TR; Cannon GW
ACR Open Rheumatol; 2023 Sep; 5(9):437-442. PubMed ID: 37491906
[TBL] [Abstract][Full Text] [Related]
2. Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study.
Kaban N; Harman H
Int J Rheum Dis; 2023 Apr; 26(4):689-698. PubMed ID: 36807751
[TBL] [Abstract][Full Text] [Related]
3. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
4. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
Alten R; Burmester GR; Matucci-Cerinic M; Salmon JH; Östör A; Ng KJ; Gerwien J; Zaremba-Pechmann L; Brnabic AJM; Fautrel B
Rheumatol Ther; 2023 Dec; 10(6):1575-1595. PubMed ID: 37755648
[TBL] [Abstract][Full Text] [Related]
6. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
[TBL] [Abstract][Full Text] [Related]
7. Patient perspectives on tapering biologic or targeted synthetic therapy in well-controlled rheumatoid arthritis and comparison with providers' perspectives.
Wiemer N; Webster P; Attur M; Yin Y; Sharma T
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv3-iv7. PubMed ID: 37855678
[TBL] [Abstract][Full Text] [Related]
8. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
[TBL] [Abstract][Full Text] [Related]
9. The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study.
Park JW; Kim MJ; Kim HA; Kim JH; Lee EB; Shin K
Front Med (Lausanne); 2022; 9():839206. PubMed ID: 35211491
[TBL] [Abstract][Full Text] [Related]
10. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
12. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
13. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Kalweit M; Burden AM; Boedecker J; Hügle T; Burkard T
PLoS Comput Biol; 2023 Jun; 19(6):e1011073. PubMed ID: 37267387
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors.
Arnold S; Jaeger VK; Scherer A; Ciurea A; Walker UA; Kyburz D
Rheumatology (Oxford); 2021 Dec; 61(1):131-138. PubMed ID: 33848332
[TBL] [Abstract][Full Text] [Related]
16. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
[TBL] [Abstract][Full Text] [Related]
17. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Glintborg B; Di Giuseppe D; Wallman JK; Nordström DC; Gudbjornsson B; Hetland ML; Askling J; Grondal G; Sokka T; Provan SA; Michelsen B; Kristianslund EK; Dreyer L; Love TJ; Lindström U
Ann Rheum Dis; 2023 Jun; 82(6):820-828. PubMed ID: 36813538
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry.
Koh JH; Lee SK; Kim J; Kim HA; Shin K; Min JK
Clin Exp Rheumatol; 2021; 39(2):269-278. PubMed ID: 32324126
[TBL] [Abstract][Full Text] [Related]
19. Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany.
Krause D; Krause C; Rudolf H; Baraliakos X; Braun J; Schmitz E
Clin Rheumatol; 2021 Mar; 40(3):887-893. PubMed ID: 32822057
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
